CTT Pharmaceutical Holdings heads into its May 22 earnings date with a regulatory filing on the table and a CEO who hasn't stopped adding to his position.
The most telling signal this week is the S-1/A amendment filed with the SEC on April 15. That registration statement update coincided with a one-day drop of 12.5% in the stock — which then recovered 7.6% over the following five days, a pattern that mirrors the wider price action seen this week. The stock closed Tuesday at $0.0745, down nearly 6% on the day but up roughly 8% across the week. For an OTC micro-cap trading below a dime, that kind of daily swing is normal; what's less normal is a CEO who keeps stepping in front of it.
Ryan Khouri, who holds 13.4% of shares, has been buying consistently since at least mid-2025. His purchases range from a few hundred dollars to a $30,000 block acquisition in August. The pattern is one of regular, small-lot buying at prices between $0.025 and $0.06 — well below the current level — accumulating to a net 285,000 shares over the trailing 90-day window captured in the data (through December 17). Independent Director Katherine Cole also added 200,000 shares at $0.04 in November. The dollar amounts are small in absolute terms, but the consistency across multiple months is notable for a company this size.
Ownership concentration is extreme. Pankaj Modi holds 27.5% of shares — and added more than 9 million shares in the period ending December 2025. Khouri and Modi together control over 40% of the company. That degree of insider dominance limits float and shapes how the stock moves on any given catalyst. With a next earnings event scheduled for May 22, that dynamic is worth keeping in mind.
A note on lending data: short interest, cost to borrow, and availability figures are all 91 days old, last updated January 29. The most recent reading put short interest at just 0.04% of the free float — effectively zero — with FINRA's fortnightly data confirming only 1,428 shares short as of April 15. There is no short-selling story here. Borrow costs were running just under 4.5% at the last available read, modest by any standard. The lending market for this stock is a non-factor.
The earnings reaction history is worth noting purely as a pattern. The December 2025 announcement produced a 47.6% single-day gain and an 88% move over five days. The April 15 event — most likely the S-1/A filing rather than a formal earnings release — reversed that, with a 12.5% drop on the day before recovering. The May 22 date will be the first conventional scheduled earnings event visible in the data, and given the ownership structure and the pending registration statement, it carries more context than a typical micro-cap print. Whether the S-1/A resolves or creates uncertainty before that date is the key thing to watch.
See the live data behind this article on ORTEX.
Open CTTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
